CD8A and glioblastoma: ABNM@TMZ/OTX also increased both the percentage and absolute numbers of activated CD8+ and CD4+ T cells in blood and tumor (Figure 5G–J), confirming that prevention of GBM re‐occurrence was achieved by activating anti‐tumor immune responses together with TMZ chemotherapy.